Search

Merck, a science and technology company, has shared updates on the company's oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the [...]

Byline: Adam Piore As cancer researchers expand the frontiers of their understanding of the basic science of cancer, biotech companies are using what they've already learned to mobilize the human [...]

Portage Biotech (PRTG) has entered into a clinical trial collaboration agreement with Merck (MRK) to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda - pembrolizumab -, Merck's anti-PD-1 therapy, [...]

Talk is cheap, as they say, but Merck Mercuriadis can walk the walk. So when, in April 2019, the eloquent Hipgnosis Songs founder and CEO informed Music Week of his [...]

RBC Capital downgraded Prometheus to Sector Perform from Outperform with a price target of $200, up from $140, after Merck (MRK) announced plans to acquire the company for $10.8B in [...]

Piper Sandler analyst Yasmeen Rahimi downgraded Prometheus (RXDX) to Neutral from Overweight with a price target of $200, up from $138, after Merck (MRK) announced plans to acquire the company [...]

Credit Suisse analyst Tiago Fauth downgraded Prometheus (RXDX) to Neutral from Outperform with a $200 price target after Merck (MRK) announced plans to acquire the company for $10.8B in cash, [...]

After Merck (MRK) announced plans to acquire Prometheus Biosciences (RXDX), a clinical stage biotech pursuing a precision medicine approach for the treatment of immune-mediated diseases, for $10.8B in cash, BofA [...]

PDS Biotechnology Corporation, a clinical-stage immunotherapy company, announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter phase 3 registrational trial [...]

PDS Biotechnology announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 [...]

IAVI and Merck have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus vaccine candidate that IAVI is developing into clinical evaluation [...]

Micron (MU) plans to use the Athinia data analytics platform to create a data collaboration ecosystem aimed at digital transformation with Micron's critical suppliers. Athinia's AI-driven quality control methodology aims [...]

The Biden administration is expected to provide outlined plans to make it easier for individuals with COVID-19 to get treatments, Stephanie Armour and Jared Hopkins of The Wall Street Journal [...]

Hello, Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news: (https://www.businessinsider.com/pfizer-chief-scientist-interview-omicrons-threat-to-vaccines-2021-11) Pfizer's top scientist told Insider how the company plans to approach the Omicron variant; [...]

Pfizer stock soared more than 10% after the drugmaker said its COVID-19 pill cuts risk of severe COVID-19 by 89%. Merck stock tumbled as results reported last month from its [...]

Pfizer's experimental COVID-19 pill decreased the risk of hospitalization and death, a new study found. 'Our ability to stop living in fear is now within reach,' Pfizer's chief scientist Mikael [...]

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the European Medicines Agency (EMA) has initiated a rolling review for molnupiravir, an investigational oral [...]

Merck and Ridgeback Biotherapeutics announced that the European Medicines Agency, or EMA, has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the treatment of COVID-19 in [...]

Hello, Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news: (https://www.businessinsider.com/why-unitedhealths-optum-business-is-striking-up-partnerships-with-hospitals-2021-10) UnitedHealth has a new plan to partner with hospital systems; (https://www.businessinsider.com/jj-boosters-moderna-pfizer-provide-better-response-new-study-2021-10) A highly anticipated [...]

Merck announced collaboration in its new Bioelectronics innovation field with neuroloop GmbH -- a B. Braun subsidiary and early-stage start-up company based in Freiburg, Germany. B. Braun SE, Melsungen, Germany, [...]

Vaccinex (VCNX) announced that the first clinical sites have been activated to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer's disease [...]

Byline: Megha M Kumar President Joe Biden said Tuesday that the US expects to take delivery of enough coronavirus vaccines for all adult Americans by the end of May, two [...]

Merck, a leading science and technology company, announced collaboration with Mammoth Biosciences, for the development, scale-up and commercial production of Mammoth's CRISPR-based SARS CoV-2 diagnostic test. Mammoth's high-throughput systems will [...]

The description provided yesterday by the government's 'Operation Warp Speed' chief adviser Moncef Slaoui of a final coronavirus vaccine it plans to add to the program closely matches the details [...]

Foghorn Therapeutics could receive up to $425 million in the development deal with Merck, its first partnership with a major biopharma. One way that a cell regulates which genes in [...]

OncoSec Medical (ONCS) announced that, based upon tumor regression and associated clinical responses observed in the heavily pretreated Cohort 1 of the KEYNOTE-890 study, the Company plans to expand into [...]